nach oben

Erschienen in:

31.08.2023 | Original Communication

Real-life evaluation of the 2017 McDonald criteria for relapsing–remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time-to-diagnosis

verfasst von: Mickaël Ferrand, Jonathan Epstein, Marc Soudant, Francis Guillemin, Sophie Pittion-Vouyovitch, Marc Debouverie, Guillaume Mathey

Erschienen in: Journal of Neurology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Previous cohort studies evaluating the performances of the McDonald criteria suffered from bias regarding real-life conditions. We aimed to evaluate the probability of diagnosing relapsing–remitting multiple sclerosis (MS) at several timepoints from the first medical evaluation and the gain in time-to-diagnosis with the 2017 McDonald criteria compared with the 2001, 2005 and 2010 versions in real life.

Methods

Patients with a first demyelinating event suggestive of MS between 2002 and 2020 were included in the ReLSEP, an exhaustive and prospectively incremented registry of MS patients in North-Eastern France. We estimated the probability of being positive at the first medical evaluation and at five timepoints according to the four versions of criteria using Kaplan–Meier estimators and Cox models.

Results

A total of 2220 patients were followed up for a median of 7.1 years. At baseline, 31.7%, 32.1%, 36.6% and 54.0% of patients, respectively, fulfilled the 2001, 2005, 2010 and 2017 McDonald criteria. Using the 2017 criteria, the gain in time-to-diagnosis was 3.7 months compared with the 2010 criteria. The presence of intrathecal synthesis of immunoglobulin G in the McDonald 2017 criteria led to a 1.8-month reduction in median time-to-diagnosis compared to a version of McDonald 2017 without this criteria.

Conclusions

In real-life, the 2017 McDonald criteria revision undoubtedly shortened time-to-diagnosis.

Nur mit Berechtigung zugänglich

Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898–904. https://doi.org/10.1056/NEJM200009283431301CrossRefPubMed

Comi G, Filippi M, Barkhof F et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet Lond Engl 357:1576–1582CrossRef

PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56:1628–1636. https://doi.org/10.1212/wnl.56.12.1628CrossRef

Comi G, Martinelli V, Rodegher M et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet Lond Engl 374:1503–1511. https://doi.org/10.1016/S0140-6736(09)61259-9CrossRef

Trojano M, Pellegrini F, Paolicelli D et al (2009) Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol 66:513–520. https://doi.org/10.1002/ana.21757CrossRefPubMed

Kinkel RP, Dontchev M, Kollman C et al (2012) Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 69:183–190. https://doi.org/10.1001/archneurol.2011.1426CrossRefPubMed

Cocco E, Sardu C, Spinicci G et al (2015) Influence of treatments in multiple sclerosis disability: a cohort study. Mult Scler Houndmills Basingstoke Engl 21:433–441. https://doi.org/10.1177/1352458514546788CrossRef

Kappos L, Edan G, Freedman MS et al (2016) The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology 87:978–987. https://doi.org/10.1212/WNL.0000000000003078CrossRefPubMedPubMedCentral

Kavaliunas A, Manouchehrinia A, Stawiarz L et al (2017) Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 23:1233–1240. https://doi.org/10.1177/1352458516675039CrossRef

10.

McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127CrossRefPubMed

11.

Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 58:840–846. https://doi.org/10.1002/ana.20703CrossRefPubMed

12.

Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302. https://doi.org/10.1002/ana.22366CrossRefPubMedPubMedCentral

13.

Thompson AJ, Banwell BL, Barkhof F et al (2017) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. https://doi.org/10.1016/S1474-4422(17)30470-2CrossRefPubMed

14.

Gamraoui S, Mathey G, Debouverie M et al (2019) High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis. J Neurol 266:902–909. https://doi.org/10.1007/s00415-019-09212-4CrossRefPubMed

15.

Gobbin F, Zanoni M, Marangi A et al (2019) 2017 McDonald criteria for multiple sclerosis: Earlier diagnosis with reduced specificity? Mult Scler Relat Disord 29:23–25. https://doi.org/10.1016/j.msard.2019.01.008CrossRefPubMed

16.

van der Vries RMV, Mescheriakova JY, Wong YYM et al (2018) Application of the 2017 Revised McDonald criteria for multiple sclerosis to patients with a typical clinically isolated syndrome. JAMA Neurol 75:1392. https://doi.org/10.1001/jamaneurol.2018.2160CrossRef

17.

Habek M, Pavičić T, Ruška B et al (2018) Establishing the diagnosis of multiple sclerosis in Croatian patients with clinically isolated syndrome: 2010 versus 2017 McDonald criteria. Mult Scler Relat Disord 25:99–103. https://doi.org/10.1016/j.msard.2018.07.035CrossRefPubMed

18.

Hyun J-W, Kim W, Huh S-Y et al (2019) Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome. Mult Scler Houndmills Basingstoke Engl 25:1488–1495. https://doi.org/10.1177/1352458518790702CrossRef

19.

Miclea A, Salmen A, Wiest R et al (2019) Prediction of conversion to multiple sclerosis using the 2017 McDonald and 2016 MAGNIMS criteria in patients with clinically isolated syndrome: a retrospective single-center study. Ther Adv Neurol Disord 12:1756286419835652. https://doi.org/10.1177/1756286419835652CrossRefPubMedPubMedCentral

20.

Gaetani L, Prosperini L, Mancini A et al (2018) 2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. J Neurol 265:2684–2687. https://doi.org/10.1007/s00415-018-9048-8CrossRefPubMed

21.

Lee D-H, Peschke M, Utz KS, Linker RA (2019) Diagnostic value of the 2017 McDonald criteria in patients with a first demyelinating event suggestive of relapsing-remitting multiple sclerosis. Eur J Neurol 26:540–545. https://doi.org/10.1111/ene.13853CrossRefPubMed

22.

McNicholas N, Lockhart A, Yap SM et al (2018) New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis. Mult Scler Houndmills Basingstoke Engl. https://doi.org/10.1177/1352458518770088CrossRef

23.

Beesley R, Anderson V, Harding KE et al (2018) Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 24:1786–1787. https://doi.org/10.1177/1352458518778007CrossRef

24.

Schwenkenbecher P, Wurster U, Sühs K-W et al (2018) Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurol 17:498. https://doi.org/10.1016/S1474-4422(18)30160-1CrossRefPubMed

25.

Zhang K, Zhao Y, Liang Z et al (2020) Validity of the McDonald criteria in predicting second events in multiple sclerosis. Mult Scler Relat Disord 43:102223. https://doi.org/10.1016/j.msard.2020.102223CrossRefPubMed

26.

Pagani Cassará F, Curbelo MC, Vazquez G et al (2020) Application of the 2017 McDonald criteria for the diagnosis of multiple sclerosis after a first demyelinating event in patients from Argentina. Mult Scler Relat Disord 41:102043. https://doi.org/10.1016/j.msard.2020.102043CrossRefPubMed

27.

Zheng Y, Shen C-H, Wang S et al (2020) Application of the 2017 McDonald criteria in a Chinese population with clinically isolated syndrome. Ther Adv Neurol Disord 13:1756286419898083. https://doi.org/10.1177/1756286419898083CrossRefPubMedPubMedCentral

28.

Hacohen Y, Brownlee W, Mankad K et al (2020) Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort. Mult Scler Houndmills Basingstoke Engl 26:1372–1380. https://doi.org/10.1177/1352458519863781CrossRef

29.

Filippi M, Preziosa P, Meani A et al (2022) Performance of the 2017 and 2010 revised McDonald criteria in predicting MS diagnosis after a clinically isolated syndrome: a MAGNIMS study. Neurology 98:e1–e14. https://doi.org/10.1212/WNL.0000000000013016CrossRefPubMed

30.

Gout O, Lebrun-Frenay C, Labauge P et al (2011) Prior suggestive symptoms in one-third of patients consulting for a “first” demyelinating event. J Neurol Neurosurg Psychiatry 82:323–325. https://doi.org/10.1136/jnnp.2008.166421CrossRefPubMed

31.

Debouverie M, Pittion-Vouyovitch S, Louis S et al (2008) Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol 15:916–921. https://doi.org/10.1111/j.1468-1331.2008.02241.xCrossRefPubMed

32.

Confavreux C, Compston DA, Hommes OR et al (1992) EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 55:671–676CrossRefPubMedPubMedCentral

33.

Mathey G, Ferrand M, Epstein J, Soudant M (2022) An algorithm to determine the date when the McDonald criteria are met for the diagnosis of relapsing-remitting multiple sclerosis. Rev Neurol (Paris). https://doi.org/10.1016/j.neurol.2022.07.005CrossRefPubMed

34.

Debouverie M, Laforest L, Van Ganse E et al (2009) Earlier disability of the patients followed in Multiple Sclerosis centers compared to out-patients. Mult Scler Houndmills Basingstoke Engl 15:251–257. https://doi.org/10.1177/1352458508097919CrossRef

35.

Kappos L, Polman CH, Freedman MS et al (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242–1249. https://doi.org/10.1212/01.wnl.0000237641.33768.8dCrossRefPubMed

Titel: Real-life evaluation of the 2017 McDonald criteria for relapsing–remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time-to-diagnosis
verfasst von: Mickaël Ferrand
Jonathan Epstein
Marc Soudant
Francis Guillemin
Sophie Pittion-Vouyovitch
Marc Debouverie
Guillaume Mathey
Publikationsdatum: 31.08.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 1/2024
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-11905-w

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Impairment of oculomotor functions in patients with early to advanced amyotrophic lateral sclerosis

Cerebrospinal fluid findings in patients with neurological manifestations in post-COVID-19 syndrome

Long-term neurological symptoms after acute COVID-19 illness requiring hospitalization in adult patients: insights from the ISARIC-COVID-19 follow-up study

Phenotype-driven reanalysis reveals five novel pathogenic variants in 40 exome-negative families with Charcot–Marie–Tooth Disease

Insomnia and sleep-disordered breathing in FKRP-related limb-girdle muscular dystrophy R9. The Norwegian LGMDR9 cohort study (2020)